TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34957958

Group type: EXPERIMENTAL
Intervention: Myofascial induction therapy (MIT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (drug treatments and instrumental physical therapy)
Number of subjects: 68
Study: 34913362

Group type: EXPERIMENTAL
Intervention: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawal at week 8)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard tacrolimus dose (control group)
Number of subjects: 54
Study: 33059096

Group type: EXPERIMENTAL
Intervention: Local vibration training (LVT) during standardised rehabilitation, n=16
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with standardised rehabilitation alone, n=14
Number of subjects: 30
Study: 33259244

Group type: EXPERIMENTAL
Intervention: Arm A: vinorelbine 60 mg/m2 day 1 + day 8 in the first cycle followed by 80 mg/m2 day 1 + day 8 in the following cycles + capecitabine 1000 mg/m2 twice a day for days 1–14
Number of subjects: 120

Group type: COMPARATOR
Intervention: Arm B: vinorelbine 50 mg three times a week + capecitabine 1000 mg/m2 twice a day for days 1–14
Number of subjects: 120
Study: 36142909

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 35921175

Group type: EXPERIMENTAL
Intervention: mChemotherapy program (6-week duration, includes self-regulation activities and nurse-led support)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 94
Study: 32074743

Group type: EXPERIMENTAL
Intervention: Congenital hereditary hearing loss (CHHL) patients
Number of subjects: 14
Study: 34503866

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg, increased to 60 mg if BP not controlled, with possible hydrochlorothiazide 12.5 mg combination
Number of subjects: 241

Group type: COMPARATOR
Intervention: Perindopril arginine 2.5 mg, increased to 5 mg if BP not controlled, with possible indapamide 1.25 mg combination
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 to 60 mg with possible hydrochlorothiazide 12.5 mg combination
Number of subjects: 241

Group type: COMPARATOR
Intervention: Perindopril 2.5 to 5 mg with possible indapamide 1.25 mg combination
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study: 33545751

Group type: EXPERIMENTAL
Intervention: Alprostadil combined with tanshinone IIa injection (Group C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Alprostadil (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tanshinone IIa injection (Group B)
Number of subjects: 300
Study: 32058832

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preclass preparation and student accountability as part of TBL
Number of subjects: 0
Study: 35904188

Group type: EXPERIMENTAL
Intervention: B-Type Natriuretic Peptide (BNP)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: BNP + CHADS2
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: BNP + CHA2 DS2-VASc
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: BNP + R2 CHADS2
Number of subjects: 799
Study: 33512318

Group type: EXPERIMENTAL
Intervention: App-based intervention (Bao Hu San) including unintentional child injury and parenting education
Number of subjects: 2920

Group type: COMPARATOR
Intervention: Control group receiving only parenting education
Number of subjects: 2920
Study: 32053137

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus neoadjuvant chemotherapy (4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (NACT)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus neoadjuvant chemotherapy
Number of subjects: 250
Study: 35231608

Group type: EXPERIMENTAL
Intervention: Synchronized rTMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsynchronized rTMS
Number of subjects: 0
Study: 33033308

Group type: EXPERIMENTAL
Intervention: Stepwise regression
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Least absolute shrinkage and selection operator (LASSO)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Boosting
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Multivariate adaptive regression splines (MuARS)
Number of subjects: 201

Group type: COMPARATOR
Intervention: All four models (Stepwise regression, LASSO, Boosting, MuARS)
Number of subjects: 201
Study: 34389558

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) alone or in combination with ipilimumab (IPI) or IPI alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined assessment of TMB, inflammatory gene expression signature, and BRAF mutation status
Number of subjects: 0
Study: 32323707

Group type: EXPERIMENTAL
Intervention: Laser ablation without extension of margins (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser ablation with at least 3mm extension of margins (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated lesions)
Number of subjects: 30
Study: 36451419

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 24 supervised training sessions (strength and aerobic) for 12 weeks (2 60‐minutes sessions per week)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gametherapy group (GG) - exercise using gametherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 100
Study: 32599652

Group type: EXPERIMENTAL
Intervention: Vutrisiran (5-300 mg)
Number of subjects: 80
Study: 33956213

Group type: EXPERIMENTAL
Intervention: On-body injector (OBI)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Pre-filled syringe (PS)
Number of subjects: 308
Study: 32839797

Group type: EXPERIMENTAL
Intervention: PPE + Vit E
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PPE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vit E
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 35190440

Group type: EXPERIMENTAL
Intervention: Energy conservation education intervention (structured programme over 12 weeks with three face-to-face sessions, one booster session, and a booklet)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care from healthcare providers and a booklet at the end of the study
Number of subjects: 126
Study: 33952216

Group type: EXPERIMENTAL
Intervention: 5% TTO gel adjunctive to SRP
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone (Control Group)
Number of subjects: 30
Study: 33753755

Group type: EXPERIMENTAL
Intervention: Daily training regimen over 5 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intensive schedule of 5 sessions delivered over 2 days
Number of subjects: 47
Study: 32616109

Group type: EXPERIMENTAL
Intervention: Virtual reality-based spatial cognitive training (VR-SCT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 56
Study: 34158656

Group type: EXPERIMENTAL
Intervention: Intravenous secretin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32304422

Group type: EXPERIMENTAL
Intervention: Normothermic ex-vivo perfusion of cardiac allografts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 0
Study: 35169007

Group type: EXPERIMENTAL
Intervention: Nerinetide treatment
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Presence of iatrogenic infarcts
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Higher lesion counts
Number of subjects: 184
Study: 33619181

Group type: EXPERIMENTAL
Intervention: nntcalc R package and web application for computing NNT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nntcalc R package and web application
Number of subjects: 0
Study: 35294778

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg every 2 weeks)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Evolocumab monotherapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined intervention groups (Evolocumab and Atorvastatin)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (Atorvastatin and Evolocumab)
Number of subjects: 81
Study: 34710138

Group type: EXPERIMENTAL
Intervention: Positive news segments
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neutral news segments
Number of subjects: 62
Study: 32306153

Group type: EXPERIMENTAL
Intervention: High sodium diet (300 mmol sodium/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low sodium diet (20 mmol sodium/day)
Number of subjects: 15
Study: 35302504

Group type: EXPERIMENTAL
Intervention: Nonguided mindfulness mobile app (8-week program)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 587
Study: 33001402

Group type: EXPERIMENTAL
Intervention: Digital version of TMT-A
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Digital version of TMT-B
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Digital version of CWIT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Individual usage of computer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Individual usage of smartphone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Usability of TMT-B
Number of subjects: 50
Study: 34758516

Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticholinergic burden (ACB)
Number of subjects: 0
Study: 32888185

Group type: EXPERIMENTAL
Intervention: MOGS (myrtle and oak gall suppository)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MOGS and Metronidazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 36449413

Group type: EXPERIMENTAL
Intervention: Lecanemab (10 mg/kg every 2 weeks)
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: Lecanemab
Number of subjects: 1795
Study: 33429753

Group type: EXPERIMENTAL
Intervention: Copeptin combined with hypersensitive cardiac troponin T (hs‐cTnT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac troponin I (cTnI)
Number of subjects: 0
Study: 33327993

Group type: EXPERIMENTAL
Intervention: MRI-compatible incubator
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional neonatal transfer incubator
Number of subjects: 120
Study: 34798036

Group type: EXPERIMENTAL
Intervention: Etrolizumab (105 mg subcutaneous once every 4 weeks)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Adalimumab (160 mg on day 1, 80 mg at week 2, 40 mg at weeks 4, 6, and 8)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 358

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 33387727

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg orally, once-daily, until disease progression or voluntary withdrawal
Number of subjects: 479
Study: 36102425

Group type: EXPERIMENTAL
Intervention: Tongue ties
Number of subjects: 30

Group type: COMPARATOR
Intervention: No tongue ties (control)
Number of subjects: 30
Study: 34673898

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections for PDR
Number of subjects: 170
Study: 34501561

Group type: EXPERIMENTAL
Intervention: Free face mask distribution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no face mask distribution)
Number of subjects: 9
Study: 32217340

Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol/2wks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 35511184

Group type: EXPERIMENTAL
Intervention: Bortezomib (1 mg/m2 IV) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2 (Bor-HDM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: High-dose melphalan alone (200 mg/m2 IV) (HDM)
Number of subjects: 300
Study: 32656890

Group type: EXPERIMENTAL
Intervention: Diversion pouch bacterial contamination
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Platelet components bacterial contamination
Number of subjects: 233
Study: 37194567

Group type: EXPERIMENTAL
Intervention: Weekly POEM for 7 weeks
Number of subjects: 296

Group type: COMPARATOR
Intervention: No POEM during this period
Number of subjects: 296
Study: 34105515

Group type: EXPERIMENTAL
Intervention: DAPT use within the first year after BRS implantation
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: DAPT use between 1 and 3 years after BRS implantation
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: DAPT use
Number of subjects: 2973
Study: 32438905

Group type: EXPERIMENTAL
Intervention: Isometric contractions at 10% MVIC
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Isometric contractions at 25% MVIC
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 55
Study: 36385019

Group type: EXPERIMENTAL
Intervention: Nuestra Comunidad Saludable intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 100
Study: 34628811

Group type: EXPERIMENTAL
Intervention: High Frequency Jet Ventilation (HFJV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 60
Study: 32823519

Group type: EXPERIMENTAL
Intervention: Cadence-synchronous music
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heartrate-synchronous music
Number of subjects: 54
Study: 33510313

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/day
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg/day
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 33221468

Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy-trabeculectomy (VTT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional trabeculotomy-trabeculectomy (CTT)
Number of subjects: 17
Study: 34952738

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (standard of care)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PRP and PRGF
Number of subjects: 20
Study: 34172030

Group type: EXPERIMENTAL
Intervention: ACP-GP intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study: 35298906

Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice daily)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Chemotherapy (administered per institutional guidelines)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Rucaparib (in intention-to-treat population)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Chemotherapy (in intention-to-treat population)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 349

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 349
Study: 34067028

Group type: EXPERIMENTAL
Intervention: WBV and core-exercise (WBVEx)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Core-exercise alone (Ex)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study: 36323186

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 0
Study: 32924721

Group type: EXPERIMENTAL
Intervention: Jaw muscle palpation (PtP)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Regional PtP
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Generalized PtP
Number of subjects: 779
Study: 33277806

Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1,2-propanediol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1-propanol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 36167669

Group type: EXPERIMENTAL
Intervention: Weightlifting 1-2 times/week
Number of subjects: 99713

Group type: EXPERIMENTAL
Intervention: Aerobic MVPA without weightlifting
Number of subjects: 99713

Group type: EXPERIMENTAL
Intervention: Weightlifting (without adjustment for MVPA)
Number of subjects: 99713

Group type: COMPARATOR
Intervention: Weightlifting
Number of subjects: 99713
Study: 33595920

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation (UAI) for 60s with an Irrisafe tip (n = 28)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) using a pulsed Er:YAG laser for 60s (n = 28)
Number of subjects: 56
Study: 32792446

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg, administered as subcutaneous injections every 28 days for 72 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo, administered as subcutaneous injections every 28 days for 72 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 33878969

Group type: EXPERIMENTAL
Intervention: MBSR‐MC (Mindfulness-Based Stress Reduction for Military Cadets)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no experimental treatment)
Number of subjects: 60
Study: 34102153

Group type: EXPERIMENTAL
Intervention: 5% Povidone-Iodine (PVP-I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 56
Study: 33706823

Group type: EXPERIMENTAL
Intervention: Restriction paired with incentive (not allowed to buy FAS with benefits and 30% financial incentive on eligible F/V)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Restriction (not allowed to buy FAS with benefits)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (same food purchasing rules as SNAP)
Number of subjects: 254
Study: 33971295

Group type: EXPERIMENTAL
Intervention: 3-month sedentary behavior reduction intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sit-stand desk attachment, wrist-worn activity prompter, behavioral counseling every two weeks, and twice-weekly automated text messages
Number of subjects: 300
Study: 33211503

Group type: EXPERIMENTAL
Intervention: Subjective quality of sleep in PD
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Actigraphic-measured sleep duration and efficiency in PD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Circadian rhythm disruption in HC
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Actigraphy-derived sleep efficiency
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 106
Study: 34006559

Group type: EXPERIMENTAL
Intervention: Treatment at the hospitals
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2702
Study: 32856353

Group type: EXPERIMENTAL
Intervention: Stress management intervention program
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 170
Study: 36315180

Group type: EXPERIMENTAL
Intervention: Guided online self-navigation
Number of subjects: 407

Group type: COMPARATOR
Intervention: In-person social care assistance
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Overall engagement with offered assistance
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Using assistance for medications
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Using assistance for blood glucose supplies
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Being out of the workforce
Number of subjects: 407
Study: 33309635

Group type: EXPERIMENTAL
Intervention: 3-month exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-Exercise group
Number of subjects: 20
Study: 33220426

Group type: EXPERIMENTAL
Intervention: GLS-guided cardioprotective therapy (CPT) initiation based on ≥12% relative reduction in GLS (n=166)
Number of subjects: 331

Group type: COMPARATOR
Intervention: EF-guided cardioprotective therapy (CPT) initiation based on >10% absolute reduction of LVEF (n=165)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: GLS-guided CPT
Number of subjects: 331

Group type: COMPARATOR
Intervention: EF-guided CPT
Number of subjects: 331

Group type: COMPARATOR
Intervention: CPT in EF-guided arm
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: CPT in GLS-guided arm
Number of subjects: 331
Study: 32293509

Group type: EXPERIMENTAL
Intervention: Novel patient information resource (website and booklet)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall trial participation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Recruitment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Web analytics
Number of subjects: 62
Study: 36305922

Group type: EXPERIMENTAL
Intervention: Soft tissue graft substitute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wound dressing (control)
Number of subjects: 0
Study: 34624757

Group type: EXPERIMENTAL
Intervention: D2 (capecitabine 1800 mg + cyclophosphamide 80 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: D3 (capecitabine 2200 mg + cyclophosphamide 100 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: D1 (capecitabine 1400 mg + cyclophosphamide 60 mg)
Number of subjects: 144
Study: 35108265

Group type: EXPERIMENTAL
Intervention: Robotic-assisted lobectomy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Video-assisted lobectomy
Number of subjects: 186
Study: 34020672

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 58

Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 58
Study: 35670115

Group type: COMPARATOR
Intervention: iv metoclopramide (0.2 mg/kg) and placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: iv metoclopramide (0.2 mg/kg) and ketorolac (0.5 mg/kg)
Number of subjects: 53
Study: 34107740

Group type: EXPERIMENTAL
Intervention: Integrated Decision Aid (IDeA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (clinician discretion)
Number of subjects: 66
Study: 35994031

Group type: EXPERIMENTAL
Intervention: vCCC (virtual collaborative care clinic)
Number of subjects: 31

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 31